

Catalog	Unit
TBI2597-50MG	50 mg
TBI2597-250MG	250 mg

### Product Details

**Formal Name:** 2-[1-[[1R)-1-[3-[(E)-2-(7-Chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetate, sodium salt

**Alternate Names:** MK-0476

**Molecular Formula:** C<sub>35</sub>H<sub>35</sub>ClNO<sub>3</sub>S Na

**Formula Weight:** 608.17

**CAS Number:** 151767-02-1


**Purity:** >98%

**Formulation:** powder

**Solubility:** Soluble in DMSO (up to 60 mg/ml), in Water (up to 30 mg/ml) or in Ethanol (up to 60 mg/ml)

**Storage:** -20°C

**Stability:** ≥ 1 year.



### Applications

Leukotriene CysLT1 antagonist; GPR17 antagonist

### Functions

Potent, selective CysLT1 receptor (leukotriene D4) antagonist (K<sub>i</sub> = 0.18 nM). Displays anti-inflammatory and anti-asthmatic effects. Clinically useful agent for treatment of chronic asthma. Attenuates chronic brain injury after focal cerebral ischemia in rodent models. Decreases blood brain barrier dysfunction in mouse models. Blockade of GPR17 by montelukast elevates neural stem and progenitor proliferation.

### Application Procedures

First dissolved in DMSO (up to 60 mg/ml), in Water (up to 30 mg/ml) or in Ethanol (up to 60 mg/ml), then diluted to aqueous buffer. Solutions in DMSO, distilled water, or ethanol may be stored at -20°C for up to 1 month.

**For research use only.**